<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05791162</url>
  </required_header>
  <id_info>
    <org_study_id>2023/748</org_study_id>
    <nct_id>NCT05791162</nct_id>
  </id_info>
  <brief_title>Interest of Follicular Helper Lymphocytes / Regulatory Follicular Helper Lymphocytes Ratio in IgA Nephropathy</brief_title>
  <acronym>LYMFONI</acronym>
  <official_title>Interest of Follicular Helper Lymphocytes / Regulatory Follicular Helper Lymphocytes Ratio to Characterize and Predict Poor Prognosis Forms in IgA Nephropathy: an Exploratory Proof-of-concept Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate the relevance of the Tfh/Tfr (Follicular helper T cells/&#xD;
      Follicular regulatory T cells) ratio in patients with IgA nephropathy:&#xD;
&#xD;
        -  To identify a differential expression of the Tfh/Tfr ratio in patients considered stable&#xD;
           or progressive&#xD;
&#xD;
        -  To predict, at diagnosis, the clinical evolution of the disease (progressive or stable&#xD;
           form) in the first year.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2023</start_date>
  <completion_date type="Anticipated">April 2026</completion_date>
  <primary_completion_date type="Anticipated">April 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Form of IgA nephropathy exhibited by the patient (progressive or stable)</measure>
    <time_frame>12 months</time_frame>
    <description>Patient with a diagnosis before the start of the study: IgA nephropathy with a GFR of less than 45 ml/min/1.73 m2 and/or proteinuria &gt;0.5 g/day and/or hematuria (microscopic or macroscopic) will be considered progressive.&#xD;
Patient with diagnosis during the study: will be considered as progressive an IgA nephropathy for which the GFR will decrease compared to the inclusion (diagnosis) of more than 5 ml/min/1.73 m2 and/or with a proteinuria &gt;0.5 g/day and/or with a microscopic hematuria on at least one of the samples carried out in a period of one year after the diagnosis.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Glomerulonephritis, IGA</condition>
  <arm_group>
    <arm_group_label>IgA nephropathy in follow-up (arm 1)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Diagnosis of IgA nephropathy from 2009, with a minimum follow-up for nephropathy of 5 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Newly diagnosed IgA nephropathy (arm 2)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Diagnosis of IgA nephropathy during the study period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CD163s control (arm 3)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Diagnosis of Lupus or ANCA-associated vasculitis or polycystic kidney disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood collection</intervention_name>
    <description>Collection of 3 blood tubes at inclusion and relapse (arm 1) or at inclusion, initiation of treatment and at 3 and 6 months post-diagnosis (arm 2)</description>
    <arm_group_label>IgA nephropathy in follow-up (arm 1)</arm_group_label>
    <arm_group_label>Newly diagnosed IgA nephropathy (arm 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Urine sample</intervention_name>
    <description>Collection of 20 cc of urine at inclusion and relapse (arm 1) or at inclusion, initiation of treatment and at 3 and 6 months post-diagnosis (arm 2) or at inclusion only (arm 3)</description>
    <arm_group_label>CD163s control (arm 3)</arm_group_label>
    <arm_group_label>IgA nephropathy in follow-up (arm 1)</arm_group_label>
    <arm_group_label>Newly diagnosed IgA nephropathy (arm 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  IgA nephropathy histologically proven on renal biopsy according to KDIGO criteria,&#xD;
             with 8 permeable glomeruli (patients diagnosed from 2009 with a minimum follow-up for&#xD;
             their nephropathy of 5 years (arm 1) or patients diagnosed during the study (arm 2))&#xD;
&#xD;
        Control patients: Lupus or ANCA-associated vasculitis or polycystic kidney disease (arm 3)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Legal incapacity or limited legal capacity&#xD;
&#xD;
          -  Subjects with no social security coverage.&#xD;
&#xD;
          -  Pregnancy / No effective contraceptive method&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melchior Chabannes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nephrology, CHU Besançon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charline Vauchy, PhD.</last_name>
    <phone>0381218875</phone>
    <email>cvauchy@chu-besancon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 17, 2023</study_first_submitted>
  <study_first_submitted_qc>March 17, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2023</study_first_posted>
  <last_update_submitted>March 17, 2023</last_update_submitted>
  <last_update_submitted_qc>March 17, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Follicular helper T cells</keyword>
  <keyword>Follicular regulatory T cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
    <mesh_term>Glomerulonephritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

